Archive: Final AE Regulatory Guidance
Jun 1, 2020, 21:50 PM
Course Id :
16471
Barnett Code :
BI12682
Date :
March 13, 2017
Conf Date :
Mar 13, 2017, 08:00 AM
Price :
625.00
Site License Price :
1625.00
This web seminar presents content and impact discussion of
the FDA and Office of Human Research Protections (OHRP) Adverse Event reporting
guidance documents. The guidance documents address issues of Adverse Event
information exchange between stakeholders and propose solutions to the issues
of the quality of information being sent to the IRBs. The guidance impacts the
activities of the research site, IRB, and sponsor/CRO’s role in compiling
and/or communicating Adverse Event information during a research study,
changing the industry’s current practices.
- Appreciate the changing
regulatory climate and the impact on safety reporting in clinical trials
- Explain the global
response and recommendations for more meaningful safety reporting between
stakeholders
- Describe the FDA’s
response: January 2009 Final Guidance
- Describe the OHRP’s
response: January 2007 Final Guidance
- Recognize implications for
current practices
- Examine case scenarios
- Sites: Principal
Investigators, Clinical Research Coordinators, Managers
- Sponsors: Clinical
Research Associates, Sponsor Clinical Operations, Safety Information
Specialists, Regulatory Professionals
The course will be led by one of the following
instructors:
Elizabeth Ronk Nelson, M.P.H.
Click here for complete trainer
biographies
Hold
this course at your company! For more information, contact Naila Ganatra at +1
215.413.2471.
Sort order :
2017031300000000
topics :
- Clinical Research
- Drug Safety & Development
jobfunctions :
- Clinical Operations & Trial Management
- Clinical Quality Assurance
- Clinical Research Associate
- Clinical Research Coordinator
- Clinical Research Investigator
- Drug Safety
- Nursing
- Project Manager
- Study Site Compliance
- Training
series :
- Clinical Trials & Translational Medicine
content Id :
174411
urlAliasnm :
Web-Seminar-Archives/Final-AE-Regulatory-Guidance--Reporting/Communication-of-Safety-Information-from-Clinical-Trials-to-IRBs-March-2017/